Heusser, K. und Erger, F. und Namer, B. und Ebner, U. und Eisenhofer, G. und Haensch, C.-A. und Tank, J. und Netzer, C. und Jordan, J. (2022) Severe autonomic failure in a patient compound heterozygous for a frame shift mutation and deletion of the ganglionic acetylcholine receptor alpha-3 subunit. 33rd International Symposium on the Autonomic Nervous System, 2022-11-02 - 2022-11-05, Hawaii.
Dieses Archiv kann nicht den Volltext zur Verfügung stellen.
Kurzfassung
The alpha-3 subunit is a crucial component of the ganglionic acetylcholine receptor. Indeed, pharmacological ganglionic blockade or antagonistic antibodies against the alpha-3 subunit virtually abolish postganglionic sympathetic and parasympathetic traffic in human beings. Mutations of the CHRNA3 gene encoding the alpha-3 subunit appear to be a rare cause of autonomic failure. We encountered an 18-year-old woman who had exhibited a fixed heart rate in utero and a rocky clinical course with repeated hypoglycemic episodes following birth. She presented with warm skin, hypohidrosis, pupillary rigidity, accommodation disorder, severe orthostatic hypotension, gastrointestinal dysmotility with a megacolon, and suprapubic catheter for urinary drainage. Intraneural nerve recordings from skin and muscle fascicles showed normal afferent but missing sympathetic activity. Isometric handgrip did not increase blood pressure. Axon reflex sweating and respiratory sinus arrhythmia were minimal. Very low supine and upright plasma norepinephrine but normal levels of related precursors and metabolites as well as skin biopsy suggested the presence of biochemically intact postganglionic neurons yet defective ganglionic neurotransmission. We performed trio whole exome sequencing using the Agilent SureSelect Human All Exon v8 enrichment chemistry on an Illumina NovaSeq6000 platform. Variant calling and copy number variant detection was done using the QIAGEN CLC Genomics Workbench, variant annotation and filtering with in-house developed software. We detected the hemizygous frameshift variant c.907_908delCT (p.Lys303Asnfs*115) in trans with a heterozygous deletion of exons 5–6 in the CHRNA3 (NM_000743.5) gene in the index patient. The frameshift variant was inherited paternally, the deletion maternally. Both variants were classified as pathogenic. We describe the first case of a patient compound heterozygous for previously described frame shift mutation and a deletion of the gene encoding the alpha-3 subunit of the ganglionic acetylcholine receptor. Clinically, the condition is associated with life-long autonomic failure with severe cardiovascular, gastrointestinal, and urogenital involvement
elib-URL des Eintrags: | https://elib.dlr.de/190427/ | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dokumentart: | Konferenzbeitrag (Poster) | ||||||||||||||||||||||||||||||||||||||||
Titel: | Severe autonomic failure in a patient compound heterozygous for a frame shift mutation and deletion of the ganglionic acetylcholine receptor alpha-3 subunit | ||||||||||||||||||||||||||||||||||||||||
Autoren: |
| ||||||||||||||||||||||||||||||||||||||||
Datum: | 2022 | ||||||||||||||||||||||||||||||||||||||||
Referierte Publikation: | Ja | ||||||||||||||||||||||||||||||||||||||||
Open Access: | Nein | ||||||||||||||||||||||||||||||||||||||||
Gold Open Access: | Nein | ||||||||||||||||||||||||||||||||||||||||
In SCOPUS: | Nein | ||||||||||||||||||||||||||||||||||||||||
In ISI Web of Science: | Nein | ||||||||||||||||||||||||||||||||||||||||
Status: | veröffentlicht | ||||||||||||||||||||||||||||||||||||||||
Stichwörter: | Dysautonomia; Ganglionic acetylcholine receptor; CHRNA3 Gene; Trio whole exome sequencing | ||||||||||||||||||||||||||||||||||||||||
Veranstaltungstitel: | 33rd International Symposium on the Autonomic Nervous System | ||||||||||||||||||||||||||||||||||||||||
Veranstaltungsort: | Hawaii | ||||||||||||||||||||||||||||||||||||||||
Veranstaltungsart: | internationale Konferenz | ||||||||||||||||||||||||||||||||||||||||
Veranstaltungsbeginn: | 2 November 2022 | ||||||||||||||||||||||||||||||||||||||||
Veranstaltungsende: | 5 November 2022 | ||||||||||||||||||||||||||||||||||||||||
HGF - Forschungsbereich: | Luftfahrt, Raumfahrt und Verkehr | ||||||||||||||||||||||||||||||||||||||||
HGF - Programm: | Raumfahrt | ||||||||||||||||||||||||||||||||||||||||
HGF - Programmthema: | Forschung unter Weltraumbedingungen | ||||||||||||||||||||||||||||||||||||||||
DLR - Schwerpunkt: | Raumfahrt | ||||||||||||||||||||||||||||||||||||||||
DLR - Forschungsgebiet: | R FR - Forschung unter Weltraumbedingungen | ||||||||||||||||||||||||||||||||||||||||
DLR - Teilgebiet (Projekt, Vorhaben): | R - CardioBrain | ||||||||||||||||||||||||||||||||||||||||
Standort: | Köln-Porz | ||||||||||||||||||||||||||||||||||||||||
Institute & Einrichtungen: | Institut für Luft- und Raumfahrtmedizin Institut für Luft- und Raumfahrtmedizin > Kardiovaskuläre Luft- und Raumfahrtmedizin Institut für Luft- und Raumfahrtmedizin > Leitungsbereich ME | ||||||||||||||||||||||||||||||||||||||||
Hinterlegt von: | Schrage, Larissa | ||||||||||||||||||||||||||||||||||||||||
Hinterlegt am: | 22 Nov 2022 13:11 | ||||||||||||||||||||||||||||||||||||||||
Letzte Änderung: | 24 Apr 2024 20:51 |
Nur für Mitarbeiter des Archivs: Kontrollseite des Eintrags